Expression of high amounts of the CD117 molecule in a case of B‐cell non‐Hodgkin's lymphoma carrying the t(14:18) translocation

The c‐kit proto‐oncogen (CD117) has been described to be present in normal and neoplastic hemopoietic cells including both myeloid and lymphoid lineages. Among the normal lymphoid cells CD117 expression would be restricted to a small subset of NK‐cells, and to early T‐cell precursors and it is not expressed by normal B‐cells. Regarding chronic lymphoproliferative disorders the only data provided up to now suggests that CD117 expression is restricted to cases of Hodgkin's disease and anaplastic large‐cell lymphoma. In the present paper we describe a case of a B‐cell chronic lymphoproliferative disorder carrying the t(14:18) translocation as demonstrated by molecular studies, in which the flow cytometric immunophenotypic analysis of both peripheral blood and bone marrow samples revealed the expression of high amounts of the CD117 antigen in the surface of the clonal B‐cell population. Further studies are necessary to explore both the functional role of c‐kit expression in the neoplastic B‐cells from this patient and its potential utility for the diagnosis and follow‐up of patients with B‐cell non‐Hodgkin's lymphoma. Am. J. Hematol. 63:226–229, 2000. © 2000 Wiley‐Liss, Inc.

[1]  A. Órfão,et al.  Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. , 1998, Leukemia & lymphoma.

[2]  A. Órfão,et al.  The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). , 1998, Blood.

[3]  S. Nishikawa,et al.  Flt3/Flk-2 and c-Kit are not essential for the proliferation of B lymphoid progenitor cells in the bone marrow of the adult mouse. , 1998, Experimental hematology.

[4]  P. Musto,et al.  CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype. , 1998, Haematologica.

[5]  J. S. San Miguel,et al.  Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype. , 1998, Haematologica.

[6]  A. Órfão,et al.  Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection. , 1998, Haematologica.

[7]  H. Rodewald,et al.  Interactions between c-kit and stem cell factor are not required for B-cell development in vivo. , 1997, Blood.

[8]  A. Órfão,et al.  Expression of the CD117 antigen (C‐Kit) on normal and myelomatous plasma cells , 1996, British journal of haematology.

[9]  L. Stempora,et al.  CD117/CD34 expression in leukemic blasts. , 1996, American journal of clinical pathology.

[10]  K. Nakase,et al.  Biological characteristics of CD7(+) acute leukemia. , 1996, Leukemia & lymphoma.

[11]  D. Catovsky,et al.  C-kit receptor (CD117) expression in acute leukemia. , 1996 .

[12]  K. Welte,et al.  Absence of c-kit receptor and absent proliferative response to stem cell factor in childhood Burkitt's lymphoma cells. , 1995, Blood.

[13]  A. Órfão,et al.  Immunophenotype of c‐kit cells in normal human bone marrow: implications for the detection of minimal residual disease in AML , 1995, British journal of haematology.

[14]  Y. Miura,et al.  Expression of c-kit receptor (CD117) and CD34 in leukemic cells. , 1995, Leukemia & lymphoma.

[15]  B. Haynes,et al.  The c-kit proto-oncogene receptor is expressed on a subset of human CD3-CD4-CD8- (triple-negative) thymocytes. , 1994, Experimental hematology.

[16]  M. Harada,et al.  The c-kit molecule and the surface immunophenotype of human acute leukemia. , 1994, Leukemia & lymphoma.

[17]  S. Nishikawa,et al.  c-kit expression by B cell precursors in mouse bone marrow. Stimulation of B cell genesis by in vivo treatment with anti-c-kit antibody. , 1994, Journal of immunology.

[18]  M. Reuss-Borst,et al.  AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. , 1994, Leukemia.

[19]  V. Zagonel,et al.  Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. , 1994, Blood.

[20]  M. Caligiuri,et al.  Expression of a functional c-kit receptor on a subset of natural killer cells , 1993, The Journal of experimental medicine.

[21]  H. Kitayama,et al.  Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells. , 1993, Leukemia & lymphoma.

[22]  M. Fukumoto,et al.  c-kit gene expression in CD7-positive acute lymphoblastic leukemia: close correlation with expression of myeloid-associated antigen CD13. , 1992, Leukemia.

[23]  A. Ullrich,et al.  The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells. , 1991, Leukemia.

[24]  S. Nishikawa,et al.  Expression and function of c-kit in hemopoietic progenitor cells , 1991, The Journal of experimental medicine.

[25]  J. V. van Dongen,et al.  Analysis of immunoglobulin and T cell receptor genes. Part I: Basic and technical aspects. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[26]  M. Minden,et al.  The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia. , 1989, Leukemia.

[27]  F. Ruddle,et al.  Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus. , 1988, The EMBO journal.

[28]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[29]  L. Ashman,et al.  A murine monoclonal antibody specific for a cell-surface antigen expressed by a subgroup of human myeloid leukaemias. , 1985, Leukemia research.